Stockreport

Galectin Therapeutics IPF Patent Solidifies Platform Technology Status [Seeking Alpha]

Galectin Therapeutics Inc.  (GALT) 
Last galectin therapeutics inc. earnings: 11/12 08:00 am Check Earnings Report
PDF Summary Galectin Therapeutics (NASDAQ: GALT ) announced on June 27th its patent for the method and treatment of Idiopathic Pulmonary Fibrosis (NYSEARCA: IPF ) [Read more]